{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:51:27Z","timestamp":1777521087509,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To report the 5-year outcomes of intravitreal aflibercept in patients with macular edema due to central retinal vein occlusion (CRVO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Participants in this study were 51 treatment-na\u00efve patients with macular edema due to CRVO, who received intravitreal aflibercept 2.0 mg using a treat-and-extend regimen after a loading dose of three-monthly injections. The primary outcomes were the mean change in best-corrected visual acuity (BCVA) and central subfield thickness (CST) at month 60 compared with baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At month 60, there was a statistically significant improvement in BCVA with a mean change of 11.5 letters compared with baseline (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). A total of 19.6% of patients gained \u226515 ETDRS letters compared with baseline. Accordingly, at month 60, there was a statistically significant reduction in CST of approximately 195 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m compared with baseline (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The mean number of injections at month 60 was 23.7. At month 60, approximately 50% of patients were found to have \u201cgood\u201d treatment response, which was associated with ellipsoid zone integrity and the absence of hyperreflective foci on optical coherence tomography. It is worthy to note that 60.8% of patients achieved treatment interval of \u22658 weeks, while 31.4% of patients \u226512 weeks. Factors associated with an extended treatment interval were intact ellipsoid zone, lower baseline CST, and the absence of disorganization of inner retinal layers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>At the 5-year follow-up, intravitreal aflibercept showed a mean gain of 11.5 letters in BCVA with an average of 23.7 injections. A total of 31.4% of patients achieved a treatment interval of \u226512 weeks, while about half of patients showed good treatment response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004477","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:03:05Z","timestamp":1743786185000},"page":"1554-1562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["INTRAVITREAL AFLIBERCEPT FOR MACULAR EDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-1024","authenticated-orcid":false,"given":"Irini","family":"Chatziralli","sequence":"first","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Theofilou","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Kazantzis","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysa","family":"Agapitou","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthymios","family":"Karmiris","sequence":"additional","affiliation":[{"name":"1st Department of Ophthalmology, G. Gennimatas General Hospital, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Risi-Koziona","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Theodossiadis","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Georgalas","sequence":"additional","affiliation":[{"name":"1st Department of Ophthalmology, G. Gennimatas General Hospital, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Theodossiadis","sequence":"additional","affiliation":[{"name":"2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1445-5994.2008.01720.x","article-title":"Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management","volume":"38","author":"Yau","year":"2008","journal-title":"Intern Med J"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"R3-20250723","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains eye study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40123-023-00830-w","article-title":"Real-world management of macular edema secondary to retinal vein occlusion with intravitreal aflibercept: 24-month results from the AURIGA Observational Study","volume":"13","author":"Giocanti-Aur\u00e9gan","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.oret.2022.11.001","article-title":"Central retinal vein occlusion 36-month outcomes with anti-VEGF: the Fight retinal blindness! Registry","volume":"7","author":"Hunt","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2021.01.027","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend for macular edema in central retinal vein occlusion: the CENTERA study","volume":"227","author":"Korobelnik","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0042-123057","article-title":"Intravitreal anti-VEGF treatment in central retinal vein occlusion (CRVO): a meta-analysis of one year results","volume":"234","author":"Gerding","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12886-020-01346-8","article-title":"A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study","volume":"20","author":"O'Day","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"8310350","DOI":"10.1155\/2018\/8310350","article-title":"Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-na\u00efve patients with macular oedema secondary to central retinal vein occlusion (CRVO): a prospective 12-month, single-arm, multicentre trial","volume":"2018","author":"Garcia-Arumi","year":"2018","journal-title":"J Ophthalmol"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40123-019-0184-8","article-title":"Real-life evidence for using a treat-and-extend injection regime for patients with central retinal vein occlusion","volume":"8","author":"Eleftheriadou","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3390\/jcm12155089","article-title":"Efficacy of a modified treat-and-extend aflibercept regimen for macular oedema in eyes with central retinal vein occlusion: 2-year prospective study","volume":"12","author":"Arai","year":"2023","journal-title":"J Clin Med"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/OPTH.S344194","article-title":"Real-world data on intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 24-month outcomes","volume":"16","author":"Shimura","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.oret.2021.02.008","article-title":"Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion","volume":"5","author":"Sen","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"9397","DOI":"10.1167\/iovs.11-7797","article-title":"Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity","volume":"52","author":"Shah","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T02:00:18Z","timestamp":1753236018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004477"}},"subtitle":["5-year Results of a Real-WORLD Study (INTRAMED-CRVO)"],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004477","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}